Literature DB >> 3523804

The adoptive immunotherapy of cancer using lymphokine activated killer cells and recombinant interleukin-2.

S E Ettinghausen, S A Rosenberg.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1986        PMID： 3523804

Source DB:  PubMed          Journal:  Springer Semin Immunopathol        ISSN： 0344-4325


× No keyword cloud information.
  43 in total

Review 1.  Passive immunotherapy of cancer in animals and man.

Authors:  S A Rosenberg; W D Terry
Journal:  Adv Cancer Res       Date:  1977       Impact factor: 6.242

2.  Inhibition of established transplants of chemically induced sarcomas in syngeneic mice by lymphocytes from immunized donors.

Authors:  H Borberg; H F Oettgen; K Choudry; E J Beattie
Journal:  Int J Cancer       Date:  1972-11       Impact factor: 7.396

3.  Lymphokine-activated killer cells: a new approach to immunotherapy of cancer.

Authors:  S Rosenberg
Journal:  J Natl Cancer Inst       Date:  1985-10       Impact factor: 13.506

4.  Successful immunotherapy of murine experimental hepatic metastases with lymphokine-activated killer cells and recombinant interleukin 2.

Authors:  R Lafreniere; S A Rosenberg
Journal:  Cancer Res       Date:  1985-08       Impact factor: 12.701

5.  Biological activity of recombinant human interleukin-2 produced in Escherichia coli.

Authors:  S A Rosenberg; E A Grimm; M McGrogan; M Doyle; E Kawasaki; K Koths; D F Mark
Journal:  Science       Date:  1984-03-30       Impact factor: 47.728

6.  Adoptive immunotherapy of established pulmonary metastases with LAK cells and recombinant interleukin-2.

Authors:  J J Mulé; S Shu; S L Schwarz; S A Rosenberg
Journal:  Science       Date:  1984-09-28       Impact factor: 47.728

7.  The anti-tumor efficacy of lymphokine-activated killer cells and recombinant interleukin 2 in vivo.

Authors:  J J Mulé; S Shu; S A Rosenberg
Journal:  J Immunol       Date:  1985-07       Impact factor: 5.422

8.  Structure and expression of a cloned cDNA for human interleukin-2.

Authors:  T Taniguchi; H Matsui; T Fujita; C Takaoka; N Kashima; R Yoshimoto; J Hamuro
Journal:  Nature       Date:  1983 Mar 24-30       Impact factor: 49.962

9.  Regression and inhibition of sarcoma growth by interference with a radiosensitive T-cell population.

Authors:  K E Hellström; I Hellström; J A Kant; J D Tamerius
Journal:  J Exp Med       Date:  1978-09-01       Impact factor: 14.307

10.  Regression of established pulmonary metastases and subcutaneous tumor mediated by the systemic administration of high-dose recombinant interleukin 2.

Authors:  S A Rosenberg; J J Mulé; P J Spiess; C M Reichert; S L Schwarz
Journal:  J Exp Med       Date:  1985-05-01       Impact factor: 14.307
View more
  8 in total

1.  Interferon gamma induces lung colonization by intravenously inoculated B16 melanoma cells in parallel with enhanced expression of class I major histocompatibility complex antigens.

Authors:  K Taniguchi; M Petersson; P Höglund; R Kiessling; G Klein; K Kärre
Journal:  Proc Natl Acad Sci U S A       Date:  1987-05       Impact factor: 11.205

2.  Propagation of cytotoxic effectors from chronic myeloid leukemia patients and cloning of cytotoxic T cells.

Authors:  R Somasundaram; S H Advani; S G Gangal
Journal:  Cancer Immunol Immunother       Date:  1988       Impact factor: 6.968

3.  7-Allyl-8-oxoguanosine (loxoribine) inhibits the metastasis of B16 melanoma cells and has adjuvant activity in mice immunized with a B16 tumor vaccine.

Authors:  B L Pope; J Sigindere; E Chourmouzis; P MacIntyre; M G Goodman
Journal:  Cancer Immunol Immunother       Date:  1994-02       Impact factor: 6.968

4.  Effect of interleukin-2 on the biodistribution of technetium-99m-labelled anti-CEA monoclonal antibody in mice bearing human tumour xenografts.

Authors:  K Nakamura; A Kubo
Journal:  Eur J Nucl Med       Date:  1994-09

5.  Recruitment of exogenous macrophages into metastases at different stages of tumor growth.

Authors:  P J Bugelski; R Kirsh; C Buscarino; S P Corwin; G Poste
Journal:  Cancer Immunol Immunother       Date:  1987       Impact factor: 6.968

6.  In vivo application of recombinant interleukin 2 in the immunotherapy of established cytomegalovirus infection.

Authors:  M J Reddehase; W Mutter; U H Koszinowski
Journal:  J Exp Med       Date:  1987-03-01       Impact factor: 14.307

Review 7.  Advances in identification and selection of personalized neoantigen/T-cell pairs for autologous adoptive T cell therapies.

Authors:  Florian Kast; Christian Klein; Pablo Umaña; Alena Gros; Stephan Gasser
Journal:  Oncoimmunology       Date:  2021-01-07       Impact factor: 8.110

8.  Therapeutic Vaccination of Hematopoietic Cell Transplantation Recipients Improves Protective CD8 T-Cell Immunotherapy of Cytomegalovirus Infection.

Authors:  Kerstin M Gergely; Jürgen Podlech; Sara Becker; Kirsten Freitag; Steffi Krauter; Nicole Büscher; Rafaela Holtappels; Bodo Plachter; Matthias J Reddehase; Niels A W Lemmermann
Journal:  Front Immunol       Date:  2021-08-19       Impact factor: 7.561
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.